Sangrur

This clinical research evaluates whether giving chemotherapy and radiation therapy at the same time (concurrent treatment) is more effective than giving them one after the other (sequential treatment) for adults with stage IIB to III invasive breast cancer. The study aims to find out if concurrent treatment improves disease-free survival, affects quality of life, post-operative appearance, side effects like arm swelling (lymphoedema), and what the financial costs are for each approach. This is a Phase III randomized controlled trial comparing these two treatment strategies. Participants will be assigned to one of two groups: the sequential group will receive chemotherapy first followed by radiation therapy, while the concurrent group will receive chemotherapy and radiation therapy together. Chemotherapy will typically include taxanes and/or anthracyclines, and radiation therapy will last for three to four weeks. Both groups will undergo these treatments as part of their adjuvant therapy after surgery. During the study, participants will have follow-up visits every six months for five years to monitor for cancer recurrence, side effects, and quality of life. The primary outcome measured is disease-free survival over a three-year period starting from enrollment, with assessments every six months. Researchers will closely observe treatment effects, side effects including lymphoedema, and overall patient well-being throughout the trial.